TestAVec went to the 30th ESGCT Congress, this year held in the beautiful city of Brussels. Robert, Mike and Saqlain attended the conference to hear all about the latest advances in gene and cell therapy. A very important takeaway was the huge advancement of the field recently in getting gene therapies into clinical trials and patients. The end goal is always to improve patient's quality of life. TestAVec aim to help this by de risking vectors. Saqlain presented the hInGeTox model, with a lot of interest from academia and industry on using the model to asses the safety of their vectors. We welcome enquires on using our services to help understand your vector in greater molecular detail.
Comentarios